Recently, numerous chemicals targeting epidermal growth factor receptor (EGFR)- or vascular endothelial growth factor receptor (VEGFR)-mediated signaling pathways have been identified, providing new alternatives for CRC therapy 2. Here, EGFR is linked to colorectal carcinoma.